UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

(Alliance News) - Cambridge Cognition Holdings PLC on Tuesday said Monument Therapeutics, in which it holds a 20% stake, has partnered up on the development of a novel treatment for cognitive ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health ...

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument ...

These results support the advancement of MT1988 into Phase II clinical development, targeting CIAS and related conditions. Cambridge Cognition’s proprietary digital cognitive assessment technologies ...

The positive Phase I results, which demonstrated favourable safety and tolerability profiles for MT1988, represent an important milestone in addressing CIAS, which is a core aspect of ...

MT1988 is designed to be used alongside existing anti-psychotic medications for schizophrenia, to address the cognitive symptoms that have long remained untreated.

MANCHESTER, UNITED KINGDOM, June 23, 2025 / EINPresswire.com / -- Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial ...

Sheryl Caswell, Chief Development Officer of Monument Therapeutics, added, "The initiation of our Phase I study for MT1988 marks a significant milestone in its clinical development.